ImmuneBiotech AB, a microbiome company developing probiotics for therapeutic effect has received a grant from Sweden’s innovation agency Vinnova for industrial process development of its first product GutMagnificTM.
GutMagnificTM is a super-consortium of 5 lactobacill strains scientifically designed to address the underlying key causes of IBS. GutMagnificTM will be launched in 2019 as a probiotic food supplement. IBS is the most common functional gastrointestinal disorder, occurring in up to 15% of the population, in Sweden 1 000 000 people are affected.
Vinnova granted ImmuneBiotech funding in its call for innovation projects in companies based on the assessment that:
ImmuneBiotech is a company in the SmiLe incubator, an incubator that helps life science entrepreneurs with business coaching and laboratory accessibility. www.smileincubator.life
For more information about ImmuneBiotech: Shahram Lavasani, CEO, +46 707408661, firstname.lastname@example.org
ImmuneBiotech AB, www.immunebiotech.com
About ImmuneBiotech AB: ImmuneBiotech discovers and develops novel probiotics for therapeutic effect based on lactic acid bacteria and symbiotic formulations targeting the gut microbiota and the immune system. We deliver transformational solutions to modulate the microbiome, heal leaky gut and reduce inflammation to prevent and treat autoimmune and other chronic inflammatory conditions. ImmuneBiotech is a company in the SmiLe incubator that supports life science entrepreneurs.